Johnson & Johnson is a global healthcare leader focused on the research, development, and manufacture of products dedicated to human health and well-being. The company operates as a holding company with a diverse portfolio spanning advanced pharmaceutical therapies and medical technologies. Its core value proposition lies in delivering innovative clinical solutions across a broad range of therapeutic areas and surgical specialties.
Based on Q1 2026 filing
Focuses on novel pharmaceutical therapies across immunology, oncology, neuroscience, infectious diseases, and cardiovascular metabolism. This segment drives growth through high-value prescription drugs and complex biologic treatments.
DARZALEX, STELARA, REMICADE, TREMFYA, IMBRUVICA, ERLEADA, XARELTO, SPRAVATO, CARVYKTI, INVEGA SUSTENNA, OPSUMIT, UPTRAVI
Wholesalers, Retailers, Hospitals, Healthcare professionals
Provides a comprehensive portfolio of medical technology solutions for cardiovascular care, orthopaedics, general and advanced surgery, and vision care. The segment emphasizes interventional solutions and enabling technologies for professional clinical use.
Abiomed heart recovery technologies, Shockwave circulatory restoration products, ACUVUE contact lenses, TECNIS intraocular lenses, Mentor breast aesthetics, DePuy Synthes orthopaedic implants
Hospitals, Physicians, Nurses, Eye care professionals, Clinics
A leading global healthcare entity with significant market share in oncology and immunology, characterized by a massive R&D pipeline and a dominant position in the medical device market.
United States, Europe, Asia-Pacific, Latin America
Healthcare providers, Medical distributors, Government health programs
Raw material suppliers, Contract research organizations, Specialized chemical providers, Biotechnology patent licensors
Pharmacy benefit managers, Governmental payers (Medicare/Medicaid), Private insurance companies, Hospital procurement networks
Pfizer
PFE
Global pharmaceutical and vaccine competitor
Stryker
SYK
Direct competitor in orthopaedics and surgical technology
Merck & Co.
MRK
Competitor in oncology and immunology
AbbVie
ABBV
Competitor in immunology and oncology
Bristol-Myers Squibb
BMY
Competitor in immunology and cardiovascular segments
Abbott
ABT
Competitor in medical devices and consumer health
Medtronic
MDT
Competitor in surgical and orthopedic technologies
Boston Scientific
BSX
Competitor in surgery and interventional solutions
Procter & Gamble
PG
Competitor in consumer health and personal care products.
Intuitive Surgical
ISRG
Competes in surgical robotics, stapling, and energy products.
United Therapeutics
UTHR
Competitor with Uptravi (selexipag) and Veletri
Genmab A/S
GMAB
Owner of patent families related to DARZALEX licensed to J&J
AbbVie
ABBV
Collaboration partner for IMBRUVICA through its subsidiary Pharmacyclics
Bristol-Myers Squibb
BMY
Co-development or competitive peer in immunology and oncology
Medtronic
MDT
Major competitor and potential partner in medical technology standards
Common questions about Johnson & Johnson
Johnson & Johnson is a global healthcare leader focused on the research, development, and manufacture of products dedicated to human health and well-being. The company operates as a holding company with a diverse portfolio spanning advanced pharmaceutical therapies and medical technologies. Its core value proposition lies in delivering innovative clinical solutions across a broad range of therapeutic areas and surgical specialties.
Johnson & Johnson (JNJ) has a market capitalization of $557.82B and trades on NYSE.
Johnson & Johnson generated $96.4B in trailing twelve-month revenue with net income of $21.0B, representing a net margin of 21.8%. Gross margin stands at 67.8%, with free cash flow of $17.8B. These figures are based on the Q1 2026 filing.
Johnson & Johnson's key competitors include Pfizer, Stryker, Merck & Co., and others. These companies compete in similar markets and product categories.
Johnson & Johnson has approximately 134,400 employees.